paper_id,claim,figure_id,title,caption,local_image_path,url
PMC12383716,"Randomisation
Participants will be randomly assigned (1:1) via EPIDAT version 4.2 software (Figure 1) to one of two groups: Group 1, RIPC; Group 2, the control group (CG).",PMC12383716_figure_1,Figure 1.,Remote ischaemic preconditioning (RIPC) and control group (CG) protocols.,./data/PMC12383716/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab93/12383716/7059a6378b36/biomedicines-13-01923-g001.jpg
PMC12383716,"Figure 2 presents the flowchart detailing patient inclusion and follow-up steps, including screening, eligibility criteria, randomisation, baseline assessments, and evaluations after the intervention.",PMC12383716_figure_2,Figure 2.,"Flowchart for patient inclusion and follow-up: screening, inclusion and exclusion, randomisation, baseline testing, and postintervention testing.",./data/PMC12383716/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab93/12383716/ef3a0c2e4c58/biomedicines-13-01923-g002.jpg
PMC12383716,"Participants will be randomly assigned (1:1) via EPIDAT version 4.2 software (Figure 1) to one of two groups: Group 1, RIPC; Group 2, the control group (CG).",PMC12383716_figure_1,Figure 1.,Remote ischaemic preconditioning (RIPC) and control group (CG) protocols.,./data/PMC12383716/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ab93/12383716/7059a6378b36/biomedicines-13-01923-g001.jpg
